Drug Trial Radar · NCT07923071
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jan 2030
Study completion Jan 2032
Sponsor
- Lead sponsor
- Syndax PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to characterize the pharmacokinetic (PK) parameters of revumenib and its major metabolite, N-deethyl revumenib (M1) after a single dose of revumenib in participants with severe liver or kidney impairment or normal liver and kidney function.
Conditions
- Relapsed/Refractory (R/R) Hematologic Malignancies
- Acute Leukemia
- Refractory Leukemia
- Relapsed Leukemia
Interventions
RevumenibDrug
Administered as oral tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of RevumenibTime frame: Up to 1 day postdose
- Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of M1Time frame: Up to 1 day postdose
- Maximum Observed Concentration (Cmax) of RevumenibTime frame: Up to 1 day postdose
- Maximum Observed Concentration (Cmax) of M1Time frame: Up to 1 day postdose
- Terminal Elimination Half-Life (t1/2) of RevumenibTime frame: Up to 1 day postdose
- Terminal Elimination Half-Life (t1/2) of M1Time frame: Up to 1 day postdose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.